Business context and reporting period
Propanc Health Group Corporation (the registrant named in the filing) filed this unaudited Form 10-Q for the quarter ended September 30, 2012. Although the request metadata labels the period “2012 Q1,” the filing itself identifies the September 30, 2012 quarter. The company was a development-stage cancer-treatment research company, with no products available for sale and no products in clinical trials.
Financial performance and position
| Metric | Quarter ended September 30, 2012 | Comparison / status |
|---|---|---|
| Revenue | $0 | $0 in the 2011 comparable quarter |
| Operating expenses | $495,983 | $3,074,060 in 2011 |
| Net loss | $492,681 | $3,074,497 in 2011 |
| Comprehensive loss | $502,601 | $3,661,523 in 2011 |
| Operating cash used | $71,995 | $38,954 in 2011 |
| Cash at quarter-end | $1,071 | $12,047 at September 30, 2011 |
| Current assets / current liabilities | $22,738 / $636,727 | Working capital deficit: $613,989 |
| Total assets / stockholders’ deficit | $27,086 / $609,641 | At September 30, 2012 |
No gross profit or margins were reported because the company had no revenue. Current liabilities included $136,613 of director loans and $16,803 of other loans; the $75,000 convertible debenture was converted during the quarter. Cash financing inflows were $74,544, primarily from loans. The filing reports no investing cash flow during the quarter.
Material changes versus the comparable period
Operating expenses and net loss were substantially lower than in the 2011 quarter, principally because 2011 included $2,870,403 of amortization of prepaid shares issued for services. Research and development expense fell to $0 from $5,381, which management attributed to limited operating funds. The current-quarter loss included stock issued for services and expenses associated with share-price ratchet issuances.
Outlook, risks, contingencies and unusual items
- Management estimated that approximately $7.5 million would be needed to fund operations and the development program over the next 12–24 months. It sought additional capital, but gave no assurance financing would be available.
- The filing states both that cash, together with additional financing, was expected to fund operations until September 2013 and that the company did not have enough cash to continue operations for the next twelve months. This liquidity outlook is internally inconsistent.
- The company reported substantial doubt about its ability to continue as a going concern, citing no revenue, recurring losses, a $613,989 working capital deficit, and dependence on financing and successful product development.
- In September, the company issued additional shares to reduce prior conversion prices from $1.50 to $0.65, recording related expenses; it also issued shares for services. Subsequent to quarter-end, it received a $56,849 Australian R&D tax credit and reported further consultant share issuances.
- The lead product remained in preclinical development. The company was pursuing national-phase patent filings internationally; patent acceptance and future financing were identified as dependencies for development.
- Disclosure controls were deemed ineffective because the small staff did not provide adequate segregation of duties. Management planned to address the weakness by hiring accounting personnel when resources permitted.
- The filing reported no pending or threatened material litigation and no off-balance-sheet arrangements. It reported no market-risk disclosure as applicable.
Most important facts for investors to verify
- Whether the company secured sufficient financing and how it addressed the stated $7.5 million funding need and minimal cash balance.
- Which liquidity forecast is accurate: funding expected through September 2013 or insufficient cash for the next twelve months.
- Progress, cost, and timing of preclinical work, clinical development, and international patent filings.
- The impact of service-related and ratchet share issuances on expenses, dilution, and outstanding shares.
- Whether the material weakness in disclosure controls was remediated and whether subsequent reporting remained reliable.